JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…

Source link : https://www.medpagetoday.com/meetingcoverage/acr/118147

Author :

Publish date : 2025-10-26 21:12:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

‘If That Doesn’t Blow Your Mind’: What We Heard This Week

NHS needs up to £3bn extra to avoid cuts, health leaders warn

Related Posts

First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma

Doctors Call Health System’s Bluff on Noncompete Agreements

Emergency vs Referral Routes in Lung Cancer Care

Cosmology’s Great Debate began a century ago – and is still going

Couples-Based Cardiac Care Improves Healthy Behaviors

Secondary Cancers After NSCLC: What’s the Risk?

First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma

Doctors Call Health System’s Bluff on Noncompete Agreements

Emergency vs Referral Routes in Lung Cancer Care

Cosmology’s Great Debate began a century ago – and is still going

Couples-Based Cardiac Care Improves Healthy Behaviors

Secondary Cancers After NSCLC: What’s the Risk?

How a Rural Community Helped Uncover Allergy Defenses

Fracture Risk Seen Even With Low-Dose Prednisone

Categories

Archives